Vaxart, Inc. (VXRT)
USD 0.45
(4.92%)
USD 0.45
(4.92%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 26.51 Million USD | 22.16% |
| 2022 | 21.7 Million USD | 66.86% |
| 2021 | 13 Million USD | 80.47% |
| 2020 | 7.2 Million USD | 211.63% |
| 2019 | 2.31 Million USD | -35.95% |
| 2018 | 3.61 Million USD | -91.03% |
| 2017 | 40.25 Million USD | 13316.67% |
| 2016 | 300 Thousand USD | -57.14% |
| 2015 | 700 Thousand USD | -30.0% |
| 2014 | 1 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 5.95 Million USD | -60.85% |
| 2008 | 15.2 Million USD | -78.81% |
| 2007 | 71.73 Million USD | -34.55% |
| 2006 | 109.6 Million USD | -0.0% |
| 2005 | 109.6 Million USD | 359.68% |
| 2004 | 23.84 Million USD | -12.96% |
| 2003 | 27.39 Million USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 78.5 Million USD | -28.33% |
| 2000 | 109.53 Million USD | -3.07% |
| 1999 | 113 Million USD | -4.31% |
| 1998 | 118.1 Million USD | -2.48% |
| 1997 | 121.1 Million USD | 45.03% |
| 1996 | 83.5 Million USD | 94.64% |
| 1995 | 42.9 Million USD | 71.6% |
| 1994 | 25 Million USD | 38.12% |
| 1993 | 18.1 Million USD | -3.21% |
| 1992 | 18.7 Million USD | 179.1% |
| 1991 | 6.7 Million USD | -8.22% |
| 1990 | 7.3 Million USD | 10.61% |
| 1989 | 6.6 Million USD | -19.51% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 23.13 Million USD | -2.45% |
| 2024 Q1 | 23.71 Million USD | -10.56% |
| 2023 Q1 | 21.51 Million USD | -0.87% |
| 2023 Q2 | 20.99 Million USD | -2.42% |
| 2023 Q3 | 20.45 Million USD | -2.56% |
| 2023 Q4 | 26.51 Million USD | 29.6% |
| 2023 FY | 26.51 Million USD | 22.16% |
| 2022 Q3 | 22.16 Million USD | 74.84% |
| 2022 Q4 | 21.7 Million USD | -2.09% |
| 2022 Q1 | 12.91 Million USD | -0.71% |
| 2022 FY | 21.7 Million USD | 66.86% |
| 2022 Q2 | 12.67 Million USD | -1.83% |
| 2021 Q4 | 13 Million USD | 2.09% |
| 2021 FY | 13 Million USD | 80.47% |
| 2021 Q2 | 6.15 Million USD | -7.24% |
| 2021 Q1 | 6.63 Million USD | -7.96% |
| 2021 Q3 | 12.74 Million USD | 107.05% |
| 2020 FY | 7.2 Million USD | 211.63% |
| 2020 Q3 | 2.73 Million USD | 41.94% |
| 2020 Q2 | 1.92 Million USD | -9.5% |
| 2020 Q4 | 7.2 Million USD | 163.93% |
| 2020 Q1 | 2.12 Million USD | -8.08% |
| 2019 FY | 2.31 Million USD | -35.95% |
| 2019 Q1 | 4.23 Million USD | 17.36% |
| 2019 Q2 | 3.62 Million USD | -14.51% |
| 2019 Q4 | 2.31 Million USD | -53.44% |
| 2019 Q3 | 4.96 Million USD | 37.12% |
| 2018 Q3 | 4.09 Million USD | -9.43% |
| 2018 Q1 | 4.95 Million USD | 1550.0% |
| 2018 FY | 3.61 Million USD | -91.03% |
| 2018 Q4 | 3.61 Million USD | -11.71% |
| 2018 Q2 | 4.51 Million USD | -8.77% |
| 2017 Q1 | 400 Thousand USD | -20.0% |
| 2017 Q4 | 300 Thousand USD | 0.0% |
| 2017 FY | 40.25 Million USD | 13316.67% |
| 2017 Q3 | 300 Thousand USD | 0.0% |
| 2017 Q2 | 300 Thousand USD | -25.0% |
| 2016 Q2 | 700 Thousand USD | -12.5% |
| 2016 FY | 300 Thousand USD | -57.14% |
| 2016 Q3 | 700 Thousand USD | 0.0% |
| 2016 Q1 | 800 Thousand USD | -11.11% |
| 2016 Q4 | 500 Thousand USD | -28.57% |
| 2015 FY | 700 Thousand USD | -30.0% |
| 2015 Q4 | 900 Thousand USD | 0.0% |
| 2015 Q3 | 900 Thousand USD | -10.0% |
| 2015 Q2 | 1 Million USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | 1 Million USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q1 | 6.04 Million USD | 1.53% |
| 2010 Q2 | - USD | -100.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 Q3 | 5.86 Million USD | 1.51% |
| 2009 Q1 | 15.42 Million USD | 1.45% |
| 2009 Q2 | 5.77 Million USD | -62.56% |
| 2009 Q4 | 5.95 Million USD | 1.52% |
| 2009 FY | 5.95 Million USD | -60.85% |
| 2008 FY | 15.2 Million USD | -78.81% |
| 2008 Q2 | 40.98 Million USD | -42.89% |
| 2008 Q3 | 34.17 Million USD | -16.61% |
| 2008 Q1 | 71.76 Million USD | 0.04% |
| 2008 Q4 | 15.2 Million USD | -55.52% |
| 2007 Q4 | 71.73 Million USD | -34.49% |
| 2007 FY | 71.73 Million USD | -34.55% |
| 2007 Q3 | 109.5 Million USD | -0.04% |
| 2007 Q2 | 109.55 Million USD | -0.03% |
| 2007 Q1 | 109.58 Million USD | -0.02% |
| 2006 Q3 | 109.61 Million USD | -8.61% |
| 2006 FY | 109.6 Million USD | -0.0% |
| 2006 Q1 | 119.79 Million USD | 9.3% |
| 2006 Q2 | 119.94 Million USD | 0.12% |
| 2006 Q4 | 109.6 Million USD | -0.01% |
| 2005 Q1 | 14.49 Million USD | -39.23% |
| 2005 Q4 | 109.6 Million USD | -10.56% |
| 2005 Q3 | 122.55 Million USD | -0.94% |
| 2005 Q2 | 123.71 Million USD | 753.81% |
| 2005 FY | 109.6 Million USD | 359.68% |
| 2004 Q4 | 23.84 Million USD | 4.07% |
| 2004 FY | 23.84 Million USD | -12.96% |
| 2004 Q1 | 23.6 Million USD | -13.83% |
| 2004 Q2 | 23.89 Million USD | 1.22% |
| 2004 Q3 | 22.91 Million USD | -4.11% |
| 2003 Q2 | 10 Million USD | 0.0% |
| 2003 Q4 | 27.39 Million USD | -26.09% |
| 2003 FY | 27.39 Million USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q3 | 37.06 Million USD | 270.61% |
| 2002 FY | - USD | -100.0% |
| 2002 Q1 | 78.5 Million USD | 0.0% |
| 2002 Q2 | - USD | -100.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 Q4 | 78.5 Million USD | 0.0% |
| 2001 Q3 | 78.5 Million USD | -23.77% |
| 2001 Q2 | 102.97 Million USD | -4.97% |
| 2001 Q1 | 108.36 Million USD | -1.06% |
| 2001 FY | 78.5 Million USD | -28.33% |
| 2000 FY | 109.53 Million USD | -3.07% |
| 2000 Q4 | 109.53 Million USD | -0.94% |
| 2000 Q1 | 112.65 Million USD | -0.31% |
| 2000 Q3 | 110.57 Million USD | -3.49% |
| 2000 Q2 | 114.57 Million USD | 1.7% |
| 1999 Q1 | 112.2 Million USD | -5.0% |
| 1999 Q3 | 105.3 Million USD | -3.04% |
| 1999 Q4 | 113 Million USD | 7.32% |
| 1999 FY | 113 Million USD | -4.31% |
| 1999 Q2 | 108.6 Million USD | -3.21% |
| 1998 FY | 118.1 Million USD | -2.48% |
| 1998 Q1 | 119.1 Million USD | -1.65% |
| 1998 Q2 | 113.9 Million USD | -4.37% |
| 1998 Q3 | 114.9 Million USD | 0.88% |
| 1998 Q4 | 118.1 Million USD | 2.79% |
| 1997 FY | 121.1 Million USD | 45.03% |
| 1997 Q4 | 121.1 Million USD | 0.25% |
| 1997 Q3 | 120.8 Million USD | 19.84% |
| 1997 Q2 | 100.8 Million USD | 5.33% |
| 1997 Q1 | 95.7 Million USD | 14.61% |
| 1996 Q1 | 90.1 Million USD | 110.02% |
| 1996 Q2 | 86.5 Million USD | -4.0% |
| 1996 Q3 | 86.3 Million USD | -0.23% |
| 1996 Q4 | 83.5 Million USD | -3.24% |
| 1996 FY | 83.5 Million USD | 94.64% |
| 1995 Q3 | 42.5 Million USD | 26.87% |
| 1995 Q4 | 42.9 Million USD | 0.94% |
| 1995 FY | 42.9 Million USD | 71.6% |
| 1995 Q1 | 25.7 Million USD | 2.8% |
| 1995 Q2 | 33.5 Million USD | 30.35% |
| 1994 Q4 | 25 Million USD | -16.39% |
| 1994 FY | 25 Million USD | 38.12% |
| 1994 Q1 | 27.6 Million USD | 52.49% |
| 1994 Q2 | 27.6 Million USD | 0.0% |
| 1994 Q3 | 29.9 Million USD | 8.33% |
| 1993 Q4 | 18.1 Million USD | -16.97% |
| 1993 Q1 | 18.6 Million USD | -0.53% |
| 1993 Q2 | 19.1 Million USD | 2.69% |
| 1993 FY | 18.1 Million USD | -3.21% |
| 1993 Q3 | 21.8 Million USD | 14.14% |
| 1992 Q1 | 18.3 Million USD | 173.13% |
| 1992 Q2 | 19.1 Million USD | 4.37% |
| 1992 Q3 | 20.4 Million USD | 6.81% |
| 1992 Q4 | 18.7 Million USD | -8.33% |
| 1992 FY | 18.7 Million USD | 179.1% |
| 1991 FY | 6.7 Million USD | -8.22% |
| 1991 Q2 | 5.6 Million USD | -9.68% |
| 1991 Q3 | 10.2 Million USD | 82.14% |
| 1991 Q4 | 6.7 Million USD | -34.31% |
| 1991 Q1 | 6.2 Million USD | -15.07% |
| 1990 Q3 | 6.8 Million USD | 6.25% |
| 1990 Q1 | 4.9 Million USD | -25.76% |
| 1990 Q2 | 6.4 Million USD | 30.61% |
| 1990 FY | 7.3 Million USD | 10.61% |
| 1990 Q4 | 7.3 Million USD | 7.35% |
| 1989 Q4 | 6.6 Million USD | -20.48% |
| 1989 Q3 | 8.3 Million USD | 9.21% |
| 1989 Q2 | 7.6 Million USD | 0.0% |
| 1989 FY | 6.6 Million USD | -19.51% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| NeuroSense Therapeutics Ltd. | 142 Thousand USD | -18571.831% |
| Psyence Biomedical Ltd. | 7.65 Million USD | -246.253% |
| XOMA Corporation | 124.45 Million USD | 78.695% |
| Mesoblast Limited | 118.92 Million USD | 77.705% |
| Xeris Biopharma Holdings, Inc. | 229.19 Million USD | 88.431% |
| Aptorum Group Limited | 3.36 Million USD | -688.545% |
| Qualigen Therapeutics, Inc. | 1.29 Million USD | -1940.769% |
| HilleVax, Inc. | 51.19 Million USD | 48.208% |
| Rocket Pharmaceuticals, Inc. | 25.04 Million USD | -5.878% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -26.957% |
| Precision BioSciences, Inc. | 31.26 Million USD | 15.204% |
| Dyadic International, Inc. | 136.92 Thousand USD | -19263.32% |
| Intensity Therapeutics, Inc. | 158 Thousand USD | -16681.013% |
| IDEAYA Biosciences, Inc. | 2.87 Million USD | -823.189% |
| Eton Pharmaceuticals, Inc. | 5.45 Million USD | -386.049% |
| VYNE Therapeutics Inc. | 214 Thousand USD | -12289.72% |
| EyePoint Pharmaceuticals, Inc. | 5.46 Million USD | -384.805% |
| Adaptive Biotechnologies Corporation | 229.43 Million USD | 88.444% |
| Tenaya Therapeutics, Inc. | 12.42 Million USD | -113.41% |
| IGM Biosciences, Inc. | 40.5 Million USD | 34.543% |
| Opthea Limited | 200.62 Million USD | 86.785% |
| Milestone Pharmaceuticals Inc. | 51.77 Million USD | 48.79% |
| Abeona Therapeutics Inc. | 5.4 Million USD | -391.0% |
| Tonix Pharmaceuticals Holding Corp. | 9.81 Million USD | -170.193% |
| Ligand Pharmaceuticals Incorporated | 6.16 Million USD | -330.073% |
| NextCure, Inc. | 6.6 Million USD | -301.423% |
| Inhibikase Therapeutics, Inc. | 622 Thousand USD | -4162.68% |
| Ovid Therapeutics Inc. | 46 Million USD | 42.363% |
| CASI Pharmaceuticals, Inc. | 21.23 Million USD | -24.836% |
| Arcturus Therapeutics Holdings Inc. | 30.21 Million USD | 12.252% |
| Syros Pharmaceuticals, Inc. | 62.07 Million USD | 57.287% |
| Senti Biosciences, Inc. | 37.66 Million USD | 29.608% |
| Apollomics, Inc. | 4.66 Million USD | -468.848% |
| PureTech Health plc | 25.51 Million USD | -3.928% |
| Oncternal Therapeutics, Inc. | 318 Thousand USD | -8237.736% |
| Barinthus Biotherapeutics plc | 12.97 Million USD | -104.331% |
| Kymera Therapeutics, Inc. | 84.67 Million USD | 68.687% |
| ChromaDex Corporation | 3.27 Million USD | -709.094% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Akebia Therapeutics, Inc. | 104.18 Million USD | 74.55% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 30.417% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Gritstone bio, Inc. | 104.77 Million USD | 74.694% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| Fate Therapeutics, Inc. | 103.53 Million USD | 74.392% |
| BioXcel Therapeutics, Inc. | 101.38 Million USD | 73.848% |
| Fortress Biotech, Inc. | 88.59 Million USD | 70.072% |
| Checkpoint Therapeutics, Inc. | - USD | -Infinity% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| Lyell Immunopharma, Inc. | 63.16 Million USD | 58.026% |
| Celcuity Inc. | 37.44 Million USD | 29.195% |
| ContextLogic Inc. | 6 Million USD | -341.9% |
| GH Research PLC | 343 Thousand USD | -7630.029% |
| HOOKIPA Pharma Inc. | 6.55 Million USD | -304.238% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| Cyclacel Pharmaceuticals, Inc. | 37 Thousand USD | -71559.459% |
| ImmuCell Corporation | 11.96 Million USD | -121.517% |
| Amarin Corporation plc | 8.73 Million USD | -203.468% |
| TG Therapeutics, Inc. | 110.79 Million USD | 76.069% |
| X4 Pharmaceuticals, Inc. | 58.28 Million USD | 54.507% |
| Acelyrin, Inc. | 1.19 Million USD | -2120.603% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Seer, Inc. | 28.25 Million USD | 6.175% |
| Novavax, Inc. | 280.63 Million USD | 90.552% |
| Phathom Pharmaceuticals, Inc. | 139.03 Million USD | 80.929% |
| Jazz Pharmaceuticals plc | 5.79 Billion USD | 99.543% |
| AnaptysBio, Inc. | 17.81 Million USD | -48.838% |
| Aptevo Therapeutics Inc. | 5.39 Million USD | -391.273% |
| PMV Pharmaceuticals, Inc. | 13.28 Million USD | -99.563% |
| AbCellera Biologics Inc. | 77.38 Million USD | 65.735% |
| CorMedix Inc. | 667.63 Thousand USD | -3871.349% |
| Cartesian Therapeutics, Inc. | 10.95 Million USD | -142.026% |
| Marker Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.019% |
| Aptose Biosciences Inc. | 1 Million USD | -2525.653% |
| ZyVersa Therapeutics, Inc. | 8656.00 USD | -306207.763% |
| Soligenix, Inc. | 3.49 Million USD | -658.722% |
| Century Therapeutics, Inc. | 48.17 Million USD | 44.959% |
| Arrowhead Pharmaceuticals, Inc. | 115.17 Million USD | 76.979% |
| TransCode Therapeutics, Inc. | 450.57 Thousand USD | -5784.533% |
| Kura Oncology, Inc. | 17.2 Million USD | -54.151% |
| RAPT Therapeutics, Inc. | 6.9 Million USD | -283.927% |
| Ardelyx, Inc. | 55.98 Million USD | 52.638% |
| Ainos, Inc. | 5.96 Million USD | -344.601% |
| TScan Therapeutics, Inc. | 92.43 Million USD | 71.315% |
| Ocean Biomedical, Inc. | 2.15 Million USD | -1133.209% |
| Prothena Corporation plc | 11.83 Million USD | -124.03% |
| CytomX Therapeutics, Inc. | 13.97 Million USD | -89.738% |
| Autolus Therapeutics plc | 52.96 Million USD | 49.942% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| Adaptimmune Therapeutics plc | 25.23 Million USD | -5.068% |
| Eterna Therapeutics Inc. | 41.84 Million USD | 36.635% |
| Celularity Inc. | 65.41 Million USD | 59.469% |
| Rallybio Corporation | 392 Thousand USD | -6663.776% |
| GRI Bio, Inc. | 14 Thousand USD | -189285.714% |
| Xenetic Biosciences, Inc. | - USD | -Infinity% |
| Omeros Corporation | 338.28 Million USD | 92.162% |
| INmune Bio, Inc. | 10.43 Million USD | -154.039% |
| Heron Therapeutics, Inc. | 179.62 Million USD | 85.239% |
| SAB Biotherapeutics, Inc. | 5.9 Million USD | -348.853% |
| Pasithea Therapeutics Corp. | 81.68 Thousand USD | -32360.823% |
| Entero Therapeutics, Inc. | 826.84 Thousand USD | -3106.651% |
| Humacyte, Inc. | 58.1 Million USD | 54.37% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 54.185% |
| Coherus BioSciences, Inc. | 480.84 Million USD | 94.486% |
| Immunocore Holdings plc | 84.03 Million USD | 68.448% |
| Cocrystal Pharma, Inc. | 1.85 Million USD | -1330.869% |
| Verastem, Inc. | 41.55 Million USD | 36.198% |
| Pliant Therapeutics, Inc. | 11.37 Million USD | -133.152% |
| Histogen Inc. | 4.62 Million USD | -473.648% |
| Surrozen, Inc. | 3.37 Million USD | -684.67% |
| Blueprint Medicines Corporation | 774.12 Million USD | 96.575% |
| Organovo Holdings, Inc. | 1.39 Million USD | -1802.009% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| IO Biotech, Inc. | 2.49 Million USD | -963.111% |
| MEI Pharma, Inc. | - USD | -Infinity% |
| GT Biopharma, Inc. | 58 Thousand USD | -45613.793% |
| Centessa Pharmaceuticals plc | 84.58 Million USD | 68.655% |
| Hepion Pharmaceuticals, Inc. | 209.02 Thousand USD | -12584.911% |
| Cabaletta Bio, Inc. | 5.01 Million USD | -428.378% |
| Summit Therapeutics Inc. | 106.09 Million USD | 75.01% |
| Alaunos Therapeutics, Inc. | - USD | -Infinity% |
| Marinus Pharmaceuticals, Inc. | 110.35 Million USD | 75.975% |
| BioRestorative Therapies, Inc. | 162.31 Thousand USD | -16234.703% |
| Turnstone Biologics Corp. | 3.21 Million USD | -724.953% |
| Pulmatrix, Inc. | 8.75 Million USD | -202.81% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | 247 Thousand USD | -10634.413% |
| Aurinia Pharmaceuticals Inc. | 97.6 Million USD | 72.836% |
| Vigil Neuroscience, Inc. | 13.85 Million USD | -91.437% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 77.014% |
| Cytokinetics, Incorporated | 755.77 Million USD | 96.492% |
| Exelixis, Inc. | 189.94 Million USD | 86.041% |
| Nurix Therapeutics, Inc. | 30.61 Million USD | 13.393% |
| Apellis Pharmaceuticals, Inc. | 110.92 Million USD | 76.098% |
| Evogene Ltd. | 1.13 Million USD | -2229.877% |
| Replimune Group, Inc. | 75.86 Million USD | 65.053% |
| PDS Biotechnology Corporation | 23.85 Million USD | -11.162% |
| Hoth Therapeutics, Inc. | 55.16 Thousand USD | -47963.083% |
| Jasper Therapeutics, Inc. | 2.78 Million USD | -851.687% |
| ESSA Pharma Inc. | 80.32 Thousand USD | -32907.171% |
| TNF Pharmaceuticals, Inc. | 48.87 Thousand USD | -54154.144% |
| BioLineRx Ltd. | 11.59 Million USD | -128.746% |
| Avid Bioservices, Inc. | 207.83 Million USD | 87.243% |
| Insmed Incorporated | 1.2 Billion USD | 97.798% |
| VistaGen Therapeutics, Inc. | 2.12 Million USD | -1150.66% |
| Zentalis Pharmaceuticals, Inc. | 45.77 Million USD | 42.075% |
| Sagimet Biosciences Inc. | 65 Thousand USD | -40690.769% |
| MediWound Ltd. | 6.71 Million USD | -295.083% |
| MiMedx Group, Inc. | 48.09 Million USD | 44.876% |
| OmniAb, Inc. | 25.56 Million USD | -3.728% |
| Alector, Inc. | 38.91 Million USD | 31.872% |
| Seres Therapeutics, Inc. | 213.93 Million USD | 87.607% |
| PTC Therapeutics, Inc. | 415.02 Million USD | 93.611% |
| Mereo BioPharma Group plc | 5.95 Million USD | -345.464% |
| Zai Lab Limited | 15.15 Million USD | -74.998% |
| Revance Therapeutics, Inc. | 478.43 Million USD | 94.458% |
| Syndax Pharmaceuticals, Inc. | 1.63 Million USD | -1521.651% |
| Aura Biosciences, Inc. | 19.55 Million USD | -35.573% |
| Immunic, Inc. | 1.33 Million USD | -1887.556% |
| Dyne Therapeutics, Inc. | 27.41 Million USD | 3.287% |
| Tarsus Pharmaceuticals, Inc. | 31.73 Million USD | 16.444% |
| Veracyte, Inc. | 12.63 Million USD | -109.929% |
| InMed Pharmaceuticals Inc. | 644.86 Million USD | 95.888% |
| FibroGen, Inc. | 170.45 Million USD | 84.445% |
| SeaStar Medical Holding Corporation | 9.08 Million USD | -191.972% |
| Allakos Inc. | 41.46 Million USD | 36.057% |
| scPharmaceuticals Inc. | 40.26 Million USD | 34.158% |
| Fulcrum Therapeutics, Inc. | 10.82 Million USD | -145.024% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -17458.94% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| NLS Pharmaceutics AG | 1.63 Million USD | -1522.896% |
| Sonnet BioTherapeutics Holdings, Inc. | 203.91 Thousand USD | -12902.732% |
| Amylyx Pharmaceuticals, Inc. | 4.23 Million USD | -525.773% |
| Precigen, Inc. | 7.09 Million USD | -273.594% |
| Fortrea Holdings Inc. | 1.67 Billion USD | 98.42% |
| KalVista Pharmaceuticals, Inc. | 7.31 Million USD | -262.362% |
| Incyte Corporation | 38.28 Million USD | 30.749% |
| Alzamend Neuro, Inc. | 300.71 Thousand USD | -8717.016% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 38.578% |
| XBiotech Inc. | - USD | -Infinity% |
| Aligos Therapeutics, Inc. | 11.13 Million USD | -138.05% |
| Jasper Therapeutics, Inc. | 2.78 Million USD | -851.687% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| CRISPR Therapeutics AG | 238.63 Million USD | 88.889% |
| Akero Therapeutics, Inc. | 26.04 Million USD | -1.809% |
| Eliem Therapeutics, Inc. | 349 Thousand USD | -7497.135% |
| Lyra Therapeutics, Inc. | 26.88 Million USD | 1.365% |
| Foghorn Therapeutics Inc. | 45.07 Million USD | 41.175% |
| Agenus Inc. | 350.24 Million USD | 92.43% |
| Kiora Pharmaceuticals, Inc. | 106.89 Thousand USD | -24704.708% |
| Y-mAbs Therapeutics, Inc. | 1.41 Million USD | -1768.499% |
| Theravance Biopharma, Inc. | 45.23 Million USD | 41.387% |
| Ultragenyx Pharmaceutical Inc. | 43.16 Million USD | 38.581% |
| Metagenomi, Inc. Common Stock | 48.22 Million USD | 45.025% |
| Lexaria Bioscience Corp. | 163.96 Thousand USD | -16070.327% |
| BioCryst Pharmaceuticals, Inc. | 848.71 Million USD | 96.876% |
| UroGen Pharma Ltd. | 100.21 Million USD | 73.543% |
| Gain Therapeutics, Inc. | 1.02 Million USD | -2480.694% |
| Sutro Biopharma, Inc. | 182.74 Million USD | 85.492% |
| Creative Medical Technology Holdings, Inc. | 14.19 Thousand USD | -186697.238% |
| Lisata Therapeutics, Inc. | 305 Thousand USD | -8593.115% |
| Chemomab Therapeutics Ltd. | 392 Thousand USD | -6663.741% |
| Stoke Therapeutics, Inc. | 6.83 Million USD | -287.915% |
| Chimerix, Inc. | 2.14 Million USD | -1136.66% |
| Reneo Pharmaceuticals, Inc. | 973 Thousand USD | -2624.974% |
| Outlook Therapeutics, Inc. | 35.55 Million USD | 25.429% |
| 60 Degrees Pharmaceuticals, Inc. | 172.67 Thousand USD | -15255.035% |
| Pluri Inc. | 29.61 Million USD | 10.462% |
| Cue Biopharma, Inc. | 14.69 Million USD | -80.429% |
| MeiraGTx Holdings plc | 89.26 Million USD | 70.297% |
| Aprea Therapeutics, Inc. | - USD | -Infinity% |
| Cadrenal Therapeutics, Inc. Common Stock | 21.35 Thousand USD | -124087.354% |
| Cidara Therapeutics, Inc. | 4.87 Million USD | -443.654% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Scholar Rock Holding Corporation | 61.81 Million USD | 57.11% |
| Sana Biotechnology, Inc. | 104.09 Million USD | 74.529% |
| Elicio Therapeutics, Inc. | 6.91 Million USD | -283.316% |
| NLS Pharmaceutics AG | 1.63 Million USD | -1522.896% |
| Adlai Nortye Ltd. American Depositary Shares | 31.54 Million USD | 15.957% |
| Nutriband Inc. | 241.28 Thousand USD | -10888.665% |
| Protara Therapeutics, Inc. | 5.46 Million USD | -384.983% |
| Vor Biopharma Inc. | 35.66 Million USD | 25.648% |
| Roivant Sciences Ltd. | 499.74 Million USD | 94.695% |
| ProKidney Corp. | 4.41 Million USD | -500.816% |
| Applied Therapeutics, Inc. | 1.22 Million USD | -2062.643% |
| Daré Bioscience, Inc. | 5.31 Million USD | -398.557% |
| BridgeBio Pharma, Inc. | 1.73 Billion USD | 98.476% |
| Titan Pharmaceuticals, Inc. | 565 Thousand USD | -4592.743% |
| Bicycle Therapeutics plc | 44.95 Million USD | 41.022% |
| Tango Therapeutics, Inc. | 38.92 Million USD | 31.876% |
| Galectin Therapeutics Inc. | 71.8 Million USD | 63.076% |
| Revolution Medicines, Inc. Warrant | 87.94 Million USD | 69.851% |
| Atai Life Sciences N.V. | 16.47 Million USD | -60.925% |
| Renovaro Biosciences Inc. | 2.45 Million USD | -981.764% |
| Aerovate Therapeutics, Inc. | 675 Thousand USD | -3828.0% |
| MediciNova, Inc. | 215.92 Thousand USD | -12179.207% |
| Praxis Precision Medicines, Inc. | 2.49 Million USD | -962.685% |
| Cardio Diagnostics Holdings, Inc. | 1.26 Million USD | -2002.57% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Protagonist Therapeutics, Inc. | 1.14 Million USD | -2223.751% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 85.774% |
| Biomea Fusion, Inc. | 10.29 Million USD | -157.517% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Erasca, Inc. | 55.85 Million USD | 52.534% |
| Cullinan Oncology, Inc. | 3.59 Million USD | -638.552% |
| NRx Pharmaceuticals, Inc. | 9.16 Million USD | -189.423% |
| 4D Molecular Therapeutics, Inc. | 14.67 Million USD | -80.724% |
| Kiniksa Pharmaceuticals, Ltd. | 12.25 Million USD | -116.3% |
| bluebird bio, Inc. | 330.32 Million USD | 91.973% |
| Ventyx Biosciences, Inc. | 12.5 Million USD | -112.01% |
| Pieris Pharmaceuticals, Inc. | - USD | -Infinity% |
| Imunon, Inc. | 1.62 Million USD | -1531.918% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 97.662% |
| BioAtla, Inc. | 2.46 Million USD | -977.805% |
| Allogene Therapeutics, Inc. | 95.12 Million USD | 72.126% |
| Larimar Therapeutics, Inc. | 5.54 Million USD | -378.074% |
| DBV Technologies S.A. | 14.38 Million USD | -84.368% |
| Fortress Biotech, Inc. | 88.59 Million USD | 70.072% |
| Avidity Biosciences, Inc. | 9.85 Million USD | -169.123% |
| Kezar Life Sciences, Inc. | 18.93 Million USD | -40.041% |
| aTyr Pharma, Inc. | 15.09 Million USD | -75.648% |
| Viridian Therapeutics, Inc. | 21.04 Million USD | -25.969% |
| EyeGate Pharmaceuticals, Inc. | 326.49 Thousand USD | -8020.848% |
| Galecto, Inc. | 249 Thousand USD | -10548.193% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Tevogen Bio Holdings Inc. | 1.63 Million USD | -1524.906% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 98.232% |
| Lexicon Pharmaceuticals, Inc. | 106.06 Million USD | 75.002% |
| Entera Bio Ltd. | 390 Thousand USD | -6698.462% |
| Travere Therapeutics, Inc. | 404.78 Million USD | 93.45% |
| Sensei Biotherapeutics, Inc. | 6.2 Million USD | -327.094% |
| Xencor, Inc. | 83.43 Million USD | 68.222% |
| Orchestra BioMed Holdings, Inc. | 1.68 Million USD | -1471.666% |
| Spruce Biosciences, Inc. | 4.6 Million USD | -475.266% |
| Coeptis Therapeutics Holdings, Inc. | 1.22 Million USD | -2065.777% |
| Vanda Pharmaceuticals Inc. | 9.4 Million USD | -181.944% |
| Lexaria Bioscience Corp. | 163.96 Thousand USD | -16070.327% |
| Portage Biotech Inc. | 47 Thousand USD | -56312.766% |
| Cardio Diagnostics Holdings, Inc. | 1.26 Million USD | -2002.57% |
| Olema Pharmaceuticals, Inc. | 2.41 Million USD | -996.98% |
| OncoCyte Corporation | 2.86 Million USD | -824.155% |
| Processa Pharmaceuticals, Inc. | 150.55 Thousand USD | -17510.957% |
| Purple Biotech Ltd. | 351 Thousand USD | -7453.846% |
| CollPlant Biotechnologies Ltd. | 3.15 Million USD | -739.316% |
| Onconetix, Inc. | 9.88 Million USD | -168.204% |
| MacroGenics, Inc. | 33.97 Million USD | 21.951% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | - USD | -Infinity% |
| Apogee Therapeutics, Inc. | 2.03 Million USD | -1203.54% |
| Neumora Therapeutics, Inc. Common Stock | 5.23 Million USD | -406.863% |
| Ocuphire Pharma, Inc. | - USD | -Infinity% |
| Prime Medicine, Inc. | 13.63 Million USD | -94.484% |
| Aditxt, Inc. | 18.21 Million USD | -45.537% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Savara Inc. | 26.73 Million USD | 0.838% |
| Curis, Inc. | 2.79 Million USD | -848.962% |
| Carmell Therapeutics Corporation | 2.13 Million USD | -1141.031% |
| Adagene Inc. | 22.3 Million USD | -18.86% |
| Achieve Life Sciences, Inc. | 16.73 Million USD | -58.472% |
| BeiGene, Ltd. | 930.18 Million USD | 97.15% |
| Inhibrx Biosciences, Inc. | 210.14 Million USD | 87.383% |
| GlycoMimetics, Inc. | 808.4 Thousand USD | -3179.804% |
| Maravai LifeSciences Holdings, Inc. | 610.96 Million USD | 95.66% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| SciSparc Ltd. | 76 Thousand USD | -34786.842% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Vincerx Pharma, Inc. | 2.5 Million USD | -959.712% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Minerva Neurosciences, Inc. | 82.01 Million USD | 67.672% |
| Fresh Tracks Therapeutics, Inc. | - USD | -Infinity% |
| Arcutis Biotherapeutics, Inc. | 205.91 Million USD | 87.124% |
| Acrivon Therapeutics, Inc. Common Stock | 4.64 Million USD | -470.93% |
| Alnylam Pharmaceuticals, Inc. | 2.68 Billion USD | 99.012% |
| ADMA Biologics, Inc. | 141.41 Million USD | 81.251% |
| Rigel Pharmaceuticals, Inc. | 60.57 Million USD | 56.232% |
| Clene Inc. | 32.16 Million USD | 17.559% |
| Celldex Therapeutics, Inc. | 2.54 Million USD | -943.037% |
| Cogent Biosciences, Inc. | 18.85 Million USD | -40.635% |
| Boundless Bio, Inc. Common Stock | 2.19 Million USD | -1107.927% |
| Recursion Pharmaceuticals, Inc. | 50.67 Million USD | 47.675% |
| Adicet Bio, Inc. | 20.92 Million USD | -26.716% |
| Contineum Therapeutics, Inc. Class A Common Stock | 193.19 Million USD | 86.276% |
| Absci Corporation | 15.95 Million USD | -66.159% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 15.3 Million USD | -73.26% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 20.29 Million USD | -30.656% |
| Surrozen, Inc. | 3.37 Million USD | -684.67% |
| Generation Bio Co. | 97.89 Million USD | 72.916% |
| Astria Therapeutics, Inc. | 329 Thousand USD | -7958.967% |
| Caribou Biosciences, Inc. | 27.48 Million USD | 3.533% |
| Black Diamond Therapeutics, Inc. | 25.29 Million USD | -4.807% |
| Janux Therapeutics, Inc. | 24.54 Million USD | -8.035% |
| Invivyd, Inc. | 2.16 Million USD | -1124.665% |
| Cingulate Inc. | 3.13 Million USD | -745.715% |
| Relay Therapeutics, Inc. | 53.46 Million USD | 50.41% |
| Quoin Pharmaceuticals, Ltd. | 3523.73 USD | -752341.305% |
| Tenax Therapeutics, Inc. | 500.9 Thousand USD | -5193.24% |
| Spero Therapeutics, Inc. | 5.54 Million USD | -378.333% |
| Jaguar Health, Inc. | 35.86 Million USD | 26.062% |
| Artelo Biosciences, Inc. | 63 Thousand USD | -41985.714% |
| 2seventy bio, Inc. | 256.67 Million USD | 89.67% |
| Clearside Biomedical, Inc. | 43 Million USD | 38.341% |
| Terns Pharmaceuticals, Inc. | 603 Thousand USD | -4297.015% |
| ACADIA Pharmaceuticals Inc. | 57.2 Million USD | 53.651% |
| Capricor Therapeutics, Inc. | 5.61 Million USD | -372.439% |
| Citius Pharmaceuticals, Inc. | 481.24 Thousand USD | -5409.46% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Kronos Bio, Inc. | 28.27 Million USD | 6.218% |
| Innoviva, Inc. | 449.07 Million USD | 94.096% |
| Bolt Biotherapeutics, Inc. | 20.21 Million USD | -31.134% |
| Entrada Therapeutics, Inc. | 68.23 Million USD | 61.14% |
| ALX Oncology Holdings Inc. | 17.19 Million USD | -54.178% |
| Vir Biotechnology, Inc. | 124.54 Million USD | 78.71% |
| Evaxion Biotech A/S | 10.86 Million USD | -143.926% |
| Ocular Therapeutix, Inc. | 83.38 Million USD | 68.204% |
| Verve Therapeutics, Inc. | 74.9 Million USD | 64.604% |
| Tyra Biosciences, Inc. | 6.49 Million USD | -308.159% |
| Galmed Pharmaceuticals Ltd. | 41 Thousand USD | -64568.293% |
| Unity Biotechnology, Inc. | 26.99 Million USD | 1.764% |
| Connect Biopharma Holdings Limited | 465 Thousand USD | -5601.935% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| AlloVir, Inc. | 27.42 Million USD | 3.336% |
| ORIC Pharmaceuticals, Inc. | 10.21 Million USD | -159.61% |
| Catalyst Pharmaceuticals, Inc. | 3.55 Million USD | -645.403% |
| CERo Therapeutics Holdings, Inc. | 1.55 Million USD | -1605.08% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -2004.286% |
| Keros Therapeutics, Inc. | 14.44 Million USD | -83.564% |
| SELLAS Life Sciences Group, Inc. | 906 Thousand USD | -2826.49% |
| Crinetics Pharmaceuticals, Inc. | 51.72 Million USD | 48.743% |
| ImmunityBio, Inc. | 883.67 Million USD | 97.0% |
| Korro Bio, Inc. | 33.2 Million USD | 20.155% |
| C4 Therapeutics, Inc. | 70.97 Million USD | 62.644% |
| Kineta, Inc. | 1.31 Million USD | -1913.212% |
| Lantern Pharma Inc. | 234.47 Thousand USD | -11208.008% |
| BioVie Inc. | 6.11 Million USD | -333.842% |
| Codexis, Inc. | 22.36 Million USD | -18.557% |
| Celularity Inc. | 65.41 Million USD | 59.469% |
| Eledon Pharmaceuticals, Inc. | 383 Thousand USD | -6822.715% |
| Virax Biolabs Group Limited | 224.3 Thousand USD | -11720.776% |
| Kodiak Sciences Inc. | 181.63 Million USD | 85.402% |
| Cibus, Inc. | 24.62 Million USD | -7.689% |
| Annexon, Inc. | 31.35 Million USD | 15.439% |
| Assembly Biosciences, Inc. | 2.34 Million USD | -1032.109% |
| Moderna, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 98.176% |
| Adverum Biotechnologies, Inc. | 75.03 Million USD | 64.665% |
| Avalo Therapeutics, Inc. | 3.9 Million USD | -579.324% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| Eyenovia, Inc. | 16.1 Million USD | -64.604% |
| Puma Biotechnology, Inc. | 111.49 Million USD | 76.218% |
| Monte Rosa Therapeutics, Inc. | 46.03 Million USD | 42.41% |
| Wave Life Sciences Ltd. | 32.11 Million USD | 17.448% |
| Conduit Pharmaceuticals Inc. | 985 Thousand USD | -2591.777% |
| Xilio Therapeutics, Inc. | 11.45 Million USD | -131.422% |
| Alkermes plc | 290.73 Million USD | 90.88% |
| Arcellx, Inc. | 97.62 Million USD | 72.841% |
| Moolec Science SA | 2.64 Million USD | -902.31% |
| Cardiff Oncology, Inc. | 2.14 Million USD | -1133.783% |
| LAVA Therapeutics N.V. | 6.31 Million USD | -319.99% |
| Enanta Pharmaceuticals, Inc. | 26.51 Million USD | -0.004% |
| Regulus Therapeutics Inc. | 3.1 Million USD | -754.739% |
| Atea Pharmaceuticals, Inc. | 2.4 Million USD | -1003.83% |
| Compass Therapeutics, Inc. | 1.73 Million USD | -1429.948% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| Humacyte, Inc. | 58.1 Million USD | 54.37% |
| Acumen Pharmaceuticals, Inc. | 28.48 Million USD | 6.926% |
| Geron Corporation | 85.89 Million USD | 69.134% |
| Verrica Pharmaceuticals Inc. | 45.51 Million USD | 41.74% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Royalty Pharma plc | 6.13 Billion USD | 99.568% |
| TFF Pharmaceuticals, Inc. | 115.25 Thousand USD | -22904.841% |
| Notable Labs, Ltd. | 2.04 Million USD | -1193.997% |
| Mersana Therapeutics, Inc. | 33.83 Million USD | 21.626% |
| Structure Therapeutics Inc. | 5.45 Million USD | -386.228% |
| IN8bio, Inc. | 4.89 Million USD | -441.876% |
| 89bio, Inc. | 27.1 Million USD | 2.191% |
| DiaMedica Therapeutics Inc. | 400 Thousand USD | -6528.5% |
| Vera Therapeutics, Inc. | 53.7 Million USD | 50.633% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| Genelux Corporation | 2.51 Million USD | -952.561% |
| Trevi Therapeutics, Inc. | 1.33 Million USD | -1881.614% |
| Liquidia Corporation | 3.5 Million USD | -656.894% |
| Mustang Bio, Inc. | 2.49 Million USD | -961.409% |
| Immunovant, Inc. | 138 Thousand USD | -19113.043% |
| Vericel Corporation | 88.14 Million USD | 69.919% |
| Quantum-Si incorporated | 15.3 Million USD | -73.26% |
| Arbutus Biopharma Corporation | 8.72 Million USD | -204.025% |
| XOMA Corporation | 124.45 Million USD | 78.695% |
| ARS Pharmaceuticals, Inc. | 274 Thousand USD | -9576.642% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Pasithea Therapeutics Corp. | 81.68 Thousand USD | -32360.823% |
| Alpha Tau Medical Ltd. | 13.27 Million USD | -99.714% |
| Vaxcyte, Inc. | 29.22 Million USD | 9.273% |
| Xenon Pharmaceuticals Inc. | 10.9 Million USD | -143.181% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| NeuroBo Pharmaceuticals, Inc. | 203 Thousand USD | -12961.084% |
| Tempest Therapeutics, Inc. | 20.66 Million USD | -28.329% |
| Sol-Gel Technologies Ltd. | 1.65 Million USD | -1503.993% |
| Rhythm Pharmaceuticals, Inc. | 1.26 Million USD | -2004.286% |
| Soleno Therapeutics, Inc. | 403 Thousand USD | -6479.156% |
| Enlivex Therapeutics Ltd. | 1.03 Million USD | -2469.186% |
| PepGen Inc. | 20.1 Million USD | -31.884% |
| Moleculin Biotech, Inc. | 574 Thousand USD | -4519.164% |
| United Therapeutics Corporation | 700 Million USD | 96.212% |
| Solid Biosciences Inc. | 26.26 Million USD | -0.948% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Conduit Pharmaceuticals Inc. | 985 Thousand USD | -2591.777% |
| Immuneering Corporation | 4.46 Million USD | -494.09% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | - USD | -Infinity% |
| Telomir Pharmaceuticals, Inc. Common Stock | 101 Thousand USD | -26151.485% |
| Belite Bio, Inc | 886 Thousand USD | -2892.551% |
| Pharming Group N.V. | 171.54 Million USD | 84.544% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Bionomics Limited | 239.61 Million USD | 88.935% |
| Pyxis Oncology, Inc. | 21.33 Million USD | -24.298% |
| uniQure N.V. | 138.4 Million USD | 80.844% |
| Windtree Therapeutics, Inc. | 16.83 Million USD | -57.54% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 85.42 Million USD | 68.962% |
| Altimmune, Inc. | 671 Thousand USD | -3851.416% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | 13.27 Million USD | -99.714% |
| Peak Bio, Inc. | 10.72 Million USD | -147.29% |
| SeaStar Medical Holding Corporation | 9.08 Million USD | -191.972% |
| FibroBiologics, Inc. Common Stock | 1.74 Million USD | -1417.687% |
| Benitec Biopharma Inc. | 284 Thousand USD | -9235.915% |
| Zura Bio Limited | - USD | -Infinity% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 94.043% |
| Salarius Pharmaceuticals, Inc. | 289.64 Thousand USD | -9054.028% |
| Compugen Ltd. | 1.35 Million USD | -1862.546% |
| Elevai Labs, Inc. Common Stock | 210.48 Thousand USD | -12496.383% |
| argenx SE | 20 Million USD | -32.57% |
| Zevra Therapeutics, Inc. | 42.76 Million USD | 38.002% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| Spyre Therapeutics, Inc. | 84.55 Million USD | 68.643% |
| NKGen Biotech, Inc. Common Stock | 19.92 Million USD | -33.096% |
| Madrigal Pharmaceuticals, Inc. | 117.19 Million USD | 77.376% |
| PolyPid Ltd. | 11.77 Million USD | -125.096% |
| Aileron Therapeutics, Inc. | 91.45 Million USD | 71.01% |
| Plus Therapeutics, Inc. | 4.18 Million USD | -534.155% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Dianthus Therapeutics, Inc. | 585 Thousand USD | -4432.308% |
| Instil Bio, Inc. | 86.05 Million USD | 69.189% |
| Elevation Oncology, Inc. | 30.13 Million USD | 12.022% |
| Immunome, Inc. | 1.65 Million USD | -1506.909% |
| Verona Pharma plc | 51.32 Million USD | 48.345% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| enGene Holdings Inc. Warrants | 9.77 Million USD | -171.16% |
| Shattuck Labs, Inc. | 4.2 Million USD | -530.985% |
| LENZ Therapeutics, Inc. | 362 Thousand USD | -7224.309% |
| Design Therapeutics, Inc. | 3.05 Million USD | -769.311% |
| Leap Therapeutics, Inc. | 262 Thousand USD | -10019.847% |
| Seelos Therapeutics, Inc. | 14.22 Million USD | -86.351% |
| Achilles Therapeutics plc | 4.61 Million USD | -474.518% |
| Fractyl Health, Inc. Common Stock | 373.72 Million USD | 92.905% |
| Rani Therapeutics Holdings, Inc. | 30.09 Million USD | 11.911% |
| MoonLake Immunotherapeutics | 3.69 Million USD | -617.008% |
| Beam Therapeutics Inc. | 173.17 Million USD | 84.689% |
| Moolec Science SA | 2.64 Million USD | -902.31% |
| Longboard Pharmaceuticals, Inc. | 475 Thousand USD | -5481.895% |
| AEON Biopharma, Inc. | 278 Thousand USD | -9437.41% |
| Aadi Bioscience, Inc. | 7.02 Million USD | -277.477% |
| Enliven Therapeutics, Inc. | 335 Thousand USD | -7814.627% |
| Iovance Biotherapeutics, Inc. | 75.86 Million USD | 65.05% |
| Taysha Gene Therapies, Inc. | 61.1 Million USD | 56.611% |
| Inovio Pharmaceuticals, Inc. | 30.2 Million USD | 12.232% |
| Athira Pharma, Inc. | 1.58 Million USD | -1572.808% |
| HCW Biologics Inc. | 6.45 Million USD | -310.957% |
| XOMA Corporation | 124.45 Million USD | 78.695% |
| NeurAxis, Inc. | 224.26 Thousand USD | -11722.884% |
| Lumos Pharma, Inc. | 6.58 Million USD | -302.642% |
| enGene Holdings Inc. Common Stock | 9.77 Million USD | -171.16% |
| 180 Life Sciences Corp. | 1.32 Million USD | -1908.531% |
| Nektar Therapeutics | 230.4 Million USD | 88.492% |
| NKGen Biotech, Inc. Warrants | 19.92 Million USD | -33.096% |
| Opiant Pharmaceuticals, Inc. | 17.08 Million USD | -55.233% |
| Arvinas, Inc. | 3.4 Million USD | -679.824% |
| CERo Therapeutics Holdings, Inc. | 1.55 Million USD | -1605.08% |
| Palisade Bio, Inc. | 369 Thousand USD | -7085.366% |
| Nutriband Inc. | 241.28 Thousand USD | -10888.665% |
| Tevogen Bio Holdings Inc. | 1.63 Million USD | -1524.906% |
| CG Oncology, Inc. Common stock | 826 Thousand USD | -3109.927% |
| Tourmaline Bio, Inc. | 415 Thousand USD | -6288.916% |
| Merus N.V. | 12.16 Million USD | -118.007% |
| Omega Therapeutics, Inc. | 128.42 Million USD | 79.355% |
| Neurogene Inc. | 16.25 Million USD | -63.113% |
| Mirum Pharmaceuticals, Inc. | 308.14 Million USD | 91.396% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| CervoMed Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | 28.54 Million USD | 7.102% |
| Sesen Bio, Inc. | - USD | -Infinity% |
| Quince Therapeutics, Inc. | 13.81 Million USD | -91.936% |
| Rezolute, Inc. | 2.22 Million USD | -1090.036% |
| Clene Inc. | 32.16 Million USD | 17.559% |
| Indaptus Therapeutics, Inc. | 175.05 Thousand USD | -15046.27% |
| BeyondSpring Inc. | 3.99 Million USD | -563.68% |
| Synlogic, Inc. | 17.27 Million USD | -53.482% |
| Allarity Therapeutics, Inc. | 1.3 Million USD | -1939.538% |
| Phio Pharmaceuticals Corp. | 35 Thousand USD | -75654.286% |
| Peak Bio, Inc. | 10.72 Million USD | -147.29% |
| Werewolf Therapeutics, Inc. | 51.92 Million USD | 48.936% |
| Krystal Biotech, Inc. | 8.09 Million USD | -227.576% |
| Karyopharm Therapeutics Inc. | 177.01 Million USD | 85.022% |
| SpringWorks Therapeutics, Inc. | 7.05 Million USD | -275.712% |
| Lipella Pharmaceuticals Inc. | 136.59 Thousand USD | -19310.809% |
| MannKind Corporation | 382.37 Million USD | 93.066% |
| Ikena Oncology, Inc. | 10.73 Million USD | -146.917% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 409 Thousand USD | -6382.641% |
| Gossamer Bio, Inc. | 212.46 Million USD | 87.521% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | 174 Thousand USD | -15137.931% |
| NRx Pharmaceuticals, Inc. | 9.16 Million USD | -189.423% |
| Legend Biotech Corporation | 328.67 Million USD | 91.933% |
| Mural Oncology plc | 15 Million USD | -76.654% |
| Disc Medicine, Inc. | 2.1 Million USD | -1161.97% |
| Champions Oncology, Inc. | 7.43 Million USD | -256.851% |
| REGENXBIO Inc. | 89.29 Million USD | 70.306% |
| Ensysce Biosciences, Inc. | 854.69 Thousand USD | -3002.152% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | 552.98 Thousand USD | -4694.731% |
| Edgewise Therapeutics, Inc. | 5.41 Million USD | -389.73% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | 15.65 Million USD | -69.339% |
| Cellectis S.A. | 92.85 Million USD | 71.445% |
| Longeveron Inc. | 2.04 Million USD | -1199.069% |
| Repare Therapeutics Inc. | 3.41 Million USD | -677.537% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 98.102% |
| Inozyme Pharma, Inc. | 46.59 Million USD | 43.093% |
| Revolution Medicines, Inc. | 87.94 Million USD | 69.851% |
| Nymox Pharmaceutical Corporation | 173 Thousand USD | -15226.012% |
| Third Harmonic Bio, Inc. | 3.95 Million USD | -570.731% |
| ArriVent BioPharma, Inc. Common Stock | 317 Thousand USD | -8264.038% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 175 Thousand USD | -15050.857% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 96.72% |
| Denali Therapeutics Inc. | 52.24 Million USD | 49.247% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 14.4 Million USD | -84.055% |
| Corvus Pharmaceuticals, Inc. | 1.37 Million USD | -1829.694% |
| Cingulate Inc. | 3.13 Million USD | -745.715% |
| Passage Bio, Inc. | 26.29 Million USD | -0.837% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | 6.66 Million USD | -297.809% |
| Day One Biopharmaceuticals, Inc. | 408 Thousand USD | -6398.529% |
| Oramed Pharmaceuticals Inc. | 894 Thousand USD | -2865.772% |
| Scinai Immunotherapeutics Ltd. | 20.56 Million USD | -28.953% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 2.45 Million USD | -981.709% |
| Carisma Therapeutics, Inc. | 3.12 Million USD | -748.991% |
| Unicycive Therapeutics, Inc. | 811 Thousand USD | -3169.297% |
| OmniAb, Inc. | 25.56 Million USD | -3.728% |
| Anew Medical, Inc. | 1.6 Million USD | -1551.963% |
| Fennec Pharmaceuticals Inc. | 29.58 Million USD | 10.374% |
| Lipocine Inc. | 17.16 Thousand USD | -154356.484% |
| Lexeo Therapeutics, Inc. Common Stock | 11.63 Million USD | -127.823% |
| Nautilus Biotechnology, Inc. | 34.62 Million USD | 23.432% |
| SAB Biotherapeutics, Inc. | 5.9 Million USD | -348.853% |
| G1 Therapeutics, Inc. | 57.17 Million USD | 53.625% |
| Bellerophon Therapeutics, Inc. | 203 Thousand USD | -12961.084% |
| Sage Therapeutics, Inc. | 5.16 Million USD | -413.34% |
| Ocugen, Inc. | 6.94 Million USD | -281.991% |
| Mind Medicine (MindMed) Inc. | 14.12 Million USD | -87.657% |
| Q32 Bio Inc. | 1.31 Million USD | -1911.684% |
| Brainstorm Cell Therapeutics Inc. | 672 Thousand USD | -3845.536% |
| Alumis Inc. Common Stock | 32.58 Million USD | 18.619% |
| Equillium, Inc. | 824 Thousand USD | -3117.718% |
| Kyverna Therapeutics, Inc. | 9.07 Million USD | -192.037% |
| Coya Therapeutics, Inc. | - USD | -Infinity% |
| CNS Pharmaceuticals, Inc. | 300.8 Thousand USD | -8714.319% |
| Dominari Holdings Inc. | 3.02 Million USD | -775.627% |
| Edesa Biotech, Inc. | 94.48 Thousand USD | -27961.003% |
| vTv Therapeutics Inc. | 529 Thousand USD | -4912.098% |
| Bio-Techne Corporation | 419.53 Million USD | 93.68% |
| Agios Pharmaceuticals, Inc. | 71.99 Million USD | 63.173% |
| Harmony Biosciences Holdings, Inc. | 193.56 Million USD | 86.302% |
| Prelude Therapeutics Incorporated | 16.88 Million USD | -56.999% |
| Candel Therapeutics, Inc. | 22.76 Million USD | -16.484% |
| iTeos Therapeutics, Inc. | 6.05 Million USD | -337.669% |
| Nkarta, Inc. | 88.33 Million USD | 69.986% |
| BioCardia, Inc. | 1.31 Million USD | -1916.274% |
| Iterum Therapeutics plc | 19.5 Million USD | -35.907% |